Israeli biotechnology company Kadimastem announces today that only one day after approaching the FDA regarding the cellular treatment that it is developing for ALS, an encouraging response was received. Based on the quality of the data presented, the FDA recommends rapidly moving forward in the approval process towards product development and safety .
http://ift.tt/1qagYp5
http://ift.tt/1qagYp5
No comments:
Post a Comment